Want to see MNKD full AI Analyst Report?
MNKD Stock Chart & Stats
$2.84
-$0.05(-0.80%)
At close: 4:00 PM EST
$2.84
-$0.05(-0.80%)
Day’s Range― - ―
52-Week Range$2.23 - $6.51
Previous CloseN/A
Volume434.88K
Average Volume (3M)6.05M
Market Cap
$1.40B
Enterprise Value$1.59B
Total Cash (Recent Filing)$133.86M
Total Debt (Recent Filing)$436.67M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 12, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding308,950,160
10 Day Avg. Volume5,194,385
30 Day Avg. Volume6,053,150
Financial Highlights & Ratios
PEG Ratio-3.54
Price to Book (P/B)-33.97
Price to Sales (P/S)4.97
P/FCF Ratio126.60
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue4.42
Enterprise Value/Gross Profit5.82
Enterprise Value/Ebitda57.89
Forecast
1Y Price Target
$8.15Price Target Upside186.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$461.85M
Bulls Say, Bears Say
Bulls Say
Revenue Scale & High Gross MarginsMannKind has meaningfully scaled top-line sales over several years while maintaining very high gross margins (~79% TTM). That durable mix supports operating leverage and cash generation capacity, enabling reinvestment in commercial expansion and pipeline programs over the next 2–6 months.
Afrezza Pediatric ApprovalThe FDA pediatric approval expands Afrezza's addressable population and fulfills a post‑marketing obligation, reducing regulatory overhang. A broader label increases long-term prescription potential and supports sustainable revenue growth as pediatric prescribing patterns and lifetime insulin needs are structural drivers.
Durable Manufacturing Partner RevenueA sole‑manufacturer supply agreement with contractual minimums for Tyvaso DPI creates predictable baseline manufacturing revenue and reinforces the inhalation platform's commercial value. Contracted volumes and royalties from partnerized products support recurring cash flow and reduce single-product concentration risk.
Bears Say
Persistent Negative Shareholders' EquityNegative shareholders' equity is a structural balance-sheet weakness that constrains financial flexibility. It can raise refinancing risk, limit strategic optionality and make future capital raises or large investments more dilutive or costly, which remains material over the coming months.
Profitability Volatility & Recent GAAP LossEarnings have swung from profit to loss as MannKind invests in launches and integration. This volatility undermines near-term free cash conversion predictability and heightens reliance on partnership receipts and milestones to fund operations, a material operational risk across the next few quarters.
Access Hurdles & Manufacturing Revenue VariabilityHigh prior‑authorization rates create persistent access friction that can limit prescription growth despite demand. Separately, manufacturing revenue is sensitive to scheduling variability at the Danbury facility, producing uneven partner income and making revenue streams less predictable in the medium term.
MannKind News
MNKD FAQ
What was MannKind Corporation’s price range in the past 12 months?
MannKind Corporation lowest stock price was $2.23 and its highest was $6.51 in the past 12 months.
What is MannKind Corporation’s market cap?
MannKind Corporation’s market cap is $1.40B.
When is MannKind Corporation’s upcoming earnings report date?
MannKind Corporation’s upcoming earnings report date is Aug 12, 2026 which is in 39 days.
How were MannKind Corporation’s earnings last quarter?
MannKind Corporation released its earnings results on May 06, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.05.
Is MannKind Corporation overvalued?
According to Wall Street analysts MannKind Corporation’s price is currently Undervalued.
Does MannKind Corporation pay dividends?
MannKind Corporation does not currently pay dividends.
What is MannKind Corporation’s EPS estimate?
MannKind Corporation’s EPS estimate is >-0.01.
How many shares outstanding does MannKind Corporation have?
MannKind Corporation has 308,950,160 shares outstanding.
What happened to MannKind Corporation’s price movement after its last earnings report?
MannKind Corporation reported an EPS of -$0.05 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went down -0.281%.
Which hedge fund is a major shareholder of MannKind Corporation?
Currently, no hedge funds are holding shares in MNKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MannKind Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.15 (186.97% Upside)
$8.15 (186.97% Upside)
Blogger Sentiment
Bullish
MNKD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 853.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.86%
12-Months-Change
Fundamentals
Return on Equity
45.59%
Trailing 12-Months
Asset Growth
81.50%
Trailing 12-Months
Company Description
MannKind Corporation
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
MNKD Company Deck
MNKD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple near-term commercial and clinical catalysts, solid top-line growth (15% YoY) and strong operational wins (FURO6 prescriber growth, royalties up 9%, SC Pharma synergies exceeding $20M), alongside meaningful progress on pipeline programs (MNKD-201 Phase 1b and Phase 2 start) and an expanded collaboration with United Therapeutics (ralinepag DPI payment and milestone potential). Short-term challenges include seasonality, field reorganization and inventory transitions that pressured Q1 revenue and contributed to GAAP and non-GAAP losses, plus some formulation and development uncertainty for new DPI programs. Management reiterated full-year FURO6 guidance and expects acceleration in H2 tied to the ReadyFlow auto-injector and Afrezza pediatrics launch, indicating confidence that near-term investments will drive longer-term growth.View all MNKD earnings summariesMNKD Stock 12 Month Forecast
Average Price Target
$8.15
▲(186.97% Upside)
Technical Analysis
Ownership Overview
2.61% Insiders
10.14% Mutual Funds
<0.01% Other Institutional Investors
72.19% Public Companies and
Individual Investors